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INTRODUCTION
INTRODUCTION
Systemic inflammation is increasingly being recognized as a risk factor 
for  a  number  of  different  complications  including  atherosclerosis1  cachexia2, 
anorexia3, and osteoporosis4.  Notably, all of these complications are commonly 
observed  in  patients  with  chronic  obstructive  pulmonary  disease  (COPD)5-10. 
Chronic  obstructive  pulmonary  disease  (COPD)  is  characterized  by  airway 
inflammation which is considered to play a pathogenic role in this disorder.  An 
increase  in  both  bronchial  and  systemic  inflammation  has  also  been 
demonstrated.  Whether systemic inflammation is present in stable COPD and 
whether  it  is  wholly  or  partially  responsible  for  these  associations  is 
controversial.  Although several studies have been undertaken to evaluate this 
potential  relationship,  most  of  the  studies  have  been  conducted  during 
exacerbations of copd and among western population.  We wanted to study the 
correlation of levels of hs-crp and plasma fibrinogen with increasing severity of 
COPD among Indian patients presenting to OPD in GGH, MMC, CHENNAI. 
We choose these markers of systemic inflammation because they have been well 
studied and have been intimately linked with the development of ischaemic heart 
disease and stroke which, interestingly, are also the leading causes of mortality 
among  patients  with  COPD. There  is  evidence  to  suggest  an  imbalance  in 
systemic levels of pro- and anti-inflammatory mediators in patients with stable 
COPD.  The presence of these proinflammatory markers in increased levels in 
patients  with  COPD  in  both  stable  state  and  during  exacerrebration  might 
predispose  them to  adverse  cardiovascular,  cerebrovascular  events11-13 acutely 
and the presence of a chronic inflammatory state may predispose to systemic 
effects such as cachexia, decreased bone mineral density with attendant risk of 
fracture, renal dysfunction, accelerated atherosclerosis, malignancy and anaemia. 
The treatment of this chronic inflammatory state and the early treatment of acute 
exacerrebration with conventional and possible newer therapeutic targets could 
possibly lead to lower incidence of these systemic effects and organ damage in 
this population. Also the role of prophylactic against these systemic and specific 
organ damage may be valuable intervention. This observative study was done to 
see if there was significant rise in the levels of these pro inflammatory marker, 
i.e., hs-CRP and plasma fibrinogen (Possibly stimulated by IL-6) as well as other 
markers such as ESR, polymorph percentage of total WBC count, pack years 
with  increasing  levels  of  severity  as  it  could  possibly  lead  to  consensus  on 
treatment protocols based on these levels during acute or chronic COPD.
         
AIMS AND OBJECTIVES
AIMS AND OBJECTIVES
            The principal aims of this study were to:
1. To determine the correlation of hs-CRP and plasma fibrinogen levels 
with  increasing  severity  of  COPD  in  80  patients  presenting  our 
hospital in GGH, CHENNAI.
2. To study the prevalence of the  levels of various systemic markers of 
inflammation  i.e.,  ESR,  hs-CRP,  plasma  fibrinogen,  polymorph 
percent of total WBC count in these  patients with COPD at different 
stages as per GOLD criteria and FEV1 percentage of predicted value. 
3. To  study  and  observe  the  relationship  between  the  distribution  of 
these  variables  in  this  group  and  correlation  with  age,  BMI,  pack 
years of smoking.
REVIEW OF LITERATURE
LITERATURE REVIEW
Chronic obstructive pulmonary disease (COPD) is a general name for the 
chronic  airflow  obstruction  that  develops  most  often  as  a  result  of  chronic 
tobacco smoking.  The pathology of COPD encompasses a variety of pathologic 
lesions in the airways, lung parenchyma, and pulmonary vasculature, and these 
lesions  can  be  correlated,  to  a  greater  or  lesser  degree,  with  changes  in 
pulmonary  function  tests  and  clinical  appearances.  In  general,  although  the 
mechanisms involved are complex, airflow obstruction can be attributed largely 
to  a  marked  increase  in  airways  resistance  secondary  to  a  variable  mix  of 
structural  abnormalities  involving  all  or  many  of  the  compartments  of  the 
airway. However, in individual cases, it may be difficult to prove associations 
between physiological abnormalities and pathologic changes. 
The recently  developed Global  Initiative  on Obstructive  Lung Disease 
(GOLD) classifies patients with COPD purely upon indices of Airflow namely 
FEV1  and  FVC.  Chronic  obstructive  pulmonary  disease  (COPD)  has  been 
defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), 
an  international  collaborative  effort  to  improve  awareness,  diagnosis,  and 
treatment of COPD, as a disease state characterized by airflow limitation that is 
not  fully  reversible.  COPD  includes  emphysema,  an  anatomically  defined 
condition characterized by destruction and enlargement of the lung alveoli; 
chronic  bronchitis,  a  clinically  defined  condition  with  chronic  cough  and 
phlegm; and small airways disease, a condition in which small bronchioles are 
narrowed. COPD is present only if chronic airflow obstruction occurs; 
COPD  is  the  fourth  leading  cause  of  death  and  affects  >16  million 
persons in the United States. COPD is also a disease of increasing public health 
importance around the world. GOLD estimates suggest that COPD will rise from 
the sixth to the third most common cause of death worldwide by 2020.
Risk Factors
Cigarette Smoking
By 1964, the Advisory Committee to the Surgeon General of the United 
States had concluded that cigarette smoking was a major risk factor for mortality 
from chronic bronchitis and emphysema. Subsequent longitudinal studies have 
shown accelerated decline in the volume of air exhaled within the first second of 
the forced expiratory maneuver (FEV1) in a dose-response relationship to the 
intensity  of  cigarette  smoking,  which  is  typically  expressed  as  pack-years 
(average number of packs of cigarettes smoked per day multiplied by the total 
number of years of smoking). This dose-response relationship between reduced 
pulmonary  function  and  cigarette  smoking  intensity  accounts  for  the  higher 
prevalence rates for COPD with increasing age.  
The  historically  higher  rate  of  smoking  among  males  is  the  likely 
explanation  for  the  higher  prevalence  of  COPD among  males;  however,  the 
prevalence of COPD among females is increasing as the gender gap in smoking 
rates has diminished in the past 50 years.
Airway Responsiveness and COPD
A tendency for increased bronchoconstriction in response to a variety of 
exogenous stimuli, including methacholine and histamine, is one of the defining 
features of asthma. However, many patients with COPD also share this feature 
of airway hyper responsiveness. The considerable overlap between persons with 
asthma and those with COPD in airway responsiveness, airflow obstruction, and 
pulmonary  symptoms  led  to  the  formulation  of  the  Dutch  hypothesis.  This 
suggests that asthma, chronic bronchitis, and emphysema are variations of the 
same basic disease, which is modulated by environmental and genetic factors to 
produce these pathologically distinct entities. The alternative British hypothesis 
contends that asthma and COPD are fundamentally different diseases: Asthma is 
viewed as largely an allergic phenomenon, while COPD results from smoking-
related inflammation and damage. Determination of the validity of the Dutch 
hypothesis  Vs.  the  British  hypothesis  awaits  identification  of  the  genetic 
predisposing  factors  for  asthma  and/or  COPD,  as  well  as  the  interactions 
between these postulated genetic factors and environmental risk factors.
Longitudinal  studies  that  compared  airway  responsiveness  at  the 
beginning  of  the  study  to  subsequent  decline  in  pulmonary  function  have 
demonstrated  that  increased  airway  responsiveness  is  clearly  a  significant 
predictor  of  subsequent  decline  in  pulmonary  function.  Thus,  airway  hyper 
responsiveness is a risk factor for COPD.
Respiratory Infections
These have been studied as potential risk factors for the development and 
progression of COPD in adults; childhood respiratory infections have also been 
assessed  as  potential  predisposing  factors  for  the  eventual  development  of 
COPD.  The  impact  of  adult  respiratory  infections  on  decline  in  pulmonary 
function  is  controversial,  but  significant  long-term  reductions  in  pulmonary 
function are not typically seen following an episode of bronchitis or pneumonia. 
The impact of the effects of childhood respiratory illnesses on the subsequent 
development of COPD has been difficult to assess due to a lack of adequate 
longitudinal data. Thus, although respiratory infections are important causes of 
exacerbations of COPD, the association of both adult and childhood respiratory 
infections to the development and progression of COPD remains to be proven.
Occupational Exposures
Increased  respiratory  symptoms  and  airflow  obstruction  have  been 
suggested as resulting from general exposure to dust at work. Several specific 
occupational exposures, including coal mining, gold mining, and cotton textile 
dust,  have  been  suggested  as  risk  factors  for  chronic  airflow  obstruction. 
However, although nonsmokers in these occupations developed some reductions 
in FEV1, the importance of dust exposure as a risk factor for COPD, independent 
of  cigarette  smoking,  is  not  certain.  Among  workers  exposed  to  cadmium 
(a  specific  chemical  fume),  FEV1,  FEV1/FVC,  and  DLCO were  significantly 
reduced (FVC, forced vital capacity; DLCO, carbon monoxide diffusing capacity 
of  the  lung)  consistent  with  airflow  obstruction  and  emphysema.  Although 
several specific occupational dusts and fumes are likely risk factors for COPD, 
the magnitude of these effects appears to be substantially less important than the 
effect of cigarette smoking.
Ambient Air Pollution
Some investigators have reported increased respiratory symptoms in those 
living in urban compared to rural areas, which may relate to increased pollution 
in  the  urban  settings.  However,  the  relationship  of  air  pollution  to  chronic 
airflow obstruction remains unproven. Prolonged exposure to smoke produced 
by biomass combustion—a common mode of cooking in some countries—also 
appears  to  be  a  significant  risk  factor  for  COPD  among  women  in  those 
countries. However, in most populations, ambient air pollution is a much less 
important risk factor for COPD than cigarette smoking.
Passive, or Second-Hand, Smoking Exposure
Exposure of children to maternal smoking results in significantly reduced 
lung growth.  In  utero tobacco smoke exposure also contributes to significant 
reductions in postnatal pulmonary function. Although passive smoke exposure 
has been associated with reductions in pulmonary function, the importance of 
this risk factor in the development of the severe pulmonary function reductions 
in COPD remains uncertain.
Genetic Considerations
Although cigarette smoking is the major environmental risk factor for the 
development of COPD, the development of airflow obstruction in smokers is 
highly  variable.  Severe  alpha1 antitrypsin  deficiency is  a  proven genetic  risk 
factor for COPD; there is increasing evidence that other genetic determinants 
also exist.
Antitrypsin Deficiency
Many variants  of  the  protease  inhibitor  (PI  or  SERPINA1)  locus  that 
encodes ALPHA 1 AT have been described. The common M allele is associated 
with  normal.   ALPHA 1  AT levels.   The  S  allele,  associated  with  slightly 
reduced ALPHA 1 AT levels, and the Z allele, associated with markedly reduced 
ALPHA  1  AT  levels,  also  occur  with  frequencies  >1%  in  most  Caucasian 
populations.  Rare individuals inherit null alleles, which lead to the absence of 
any ALPHA 1 - AT production through a heterogeneous collection of mutations. 
Individuals with two Z alleles or one Z and one null allele are referred to as Pi Z, 
which is the most common form of severe ALPHA 1 AT deficiency.
Although  only  1–2%  of  COPD  patients  are  found  to  have  severe 
ALPHA  1  AT  deficiency  as  a  contributing  cause  of  COPD,  these  patients 
demonstrate  that  genetic  factors  can  have  a  profound  influence  on  the 
susceptibility for developing COPD.  Pi  Z individuals often develop early-onset 
COPD, but the ascertainment bias in the published series of Pi  Z individuals—
which have usually included many Pi Z subjects who were tested for ALPHA 1 
AT  deficiency  because  they  had  COPD—means  that  the  fraction  of  Pi  Z 
individuals who will  develop COPD and the age-of-onset distribution for the 
development of COPD in Pi  Z subjects remain unknown. Approximately 1 in 
3000 individuals in the United States inherits severe ALPHA 1 AT deficiency, 
but only a small minority of these individuals has been recognized. The clinical 
laboratory test used most frequently to screen for ALPHA 1 AT deficiency is 
measurement of the immunologic level of ALPHA 1 AT in serum.
Specific treatment in the form of ALPHA 1 AT augmentation therapy is 
available for severe AT deficiency as a weekly intravenous infusion factors. 
Other Genetic Risk Factors
Studies  of  pulmonary  function  measurements  performed  in  general 
population  samples  have  suggested  that  genetic  factors  other  than  PI  type 
influence  variation  in  pulmonary  function.  Familial  aggregation  of  airflow 
obstruction within families of COPD patients has also been demonstrated.
Natural History
The effects of cigarette smoking on pulmonary function appear to depend 
on the intensity of smoking exposure, the timing of smoking exposure during 
growth, and the baseline lung function of the individual; other environmental 
factors  may have similar  effects.  Although rare  individuals  may demonstrate 
precipitous  declines  in  pulmonary  function,  most  individuals  follow a  steady 
trajectory of increasing pulmonary function with growth during childhood and 
adolescence,  followed by a gradual decline with aging.  Individuals  appear to 
track  in  their  quartile  of  pulmonary  function  based  upon  environmental  and 
genetic factors that put them on different tracks. The risk of eventual mortality 
from COPD is  closely  associated  with  reduced  levels  of  FEV1.  The  rate  of 
decline  in  pulmonary  function  can  be  modified  by  changing  environmental 
exposures  (i.e.,  quitting  smoking),  with  smoking  cessation  at  an  earlier  age 
providing  a  more  beneficial  effect  than  smoking  cessation  after  marked 
reductions in pulmonary function have already developed. Genetic factors likely 
contribute to the level of pulmonary function achieved during growth and to the 
rate of decline in response to smoking and potentially to other environmental 
factors as well.
The Elastase : Antielastase Hypothesis 
Elastin, the principal component of elastic fibers, is a highly stable component 
of the extra cellular matrix that is critical to the integrity of both the small airways and 
the lung parenchyma. The Elastase : Antielastase hypothesis proposed in the mid-1960s 
states that the balance of elastin-degrading enzymes and their inhibitors determines the 
susceptibility  of  the  lung  to  destruction  resulting  in  airspace  enlargement.  This 
hypothesis was based on the clinical observation that patients with genetic deficiency in 
AT, the inhibitor of the serine proteinase neutrophils Elastase, were at increased risk of 
emphysema,  and  that  instillation  of  Elastase,  including  neutrophils  Elastase,  to 
experimental animals results  in emphysema.  To this day, the Elastase :  Antielastase 
hypothesis is the prevailing mechanism for the development of emphysema. However, a 
complex network of inflammatory cells  and additional proteinases that  contribute to 
emphysema have subsequently been identified.
Inflammation and Extra cellular Matrix Proteolysis 
Macrophages patrol the lower airspace under normal conditions. Upon exposure 
to  oxidants  from  cigarette  smoke,  histone  deacetylase-2  is  inactivated,  shifting  the 
balance  toward  acetylated  or  loose  chromatin,  exposing  nuclear  factor  B  sites  and 
resulting  in  transcription  of  matrix  metalloproteinase-9,  proinflammatory  cytokines 
interleukin 8 (IL-8), and tumor necrosis factor (TNF-alpha); this leads to neutrophils 
recruitment. CD8+ T-cells are also recruited in response to cigarette smoke and release 
interferon  inducible  protein-10  (IP-10,  CXCL-7)  that  in  turn  leads  to  macrophage 
production of macrophage Elastase [matrix metalloproteinase-12 (MMP-12)].  Matrix 
metalloproteinase  and  serine  proteinases,  most  notably  neutrophil  Elastase,  work 
together by degrading the inhibitor of the other, leading to lung destruction. Proteolytic 
cleavage  products  of  elastin  also  serve  as  a  macrophage  chemokine,  fueling  this 
destructive positive feedback loop.
            Concomitant cigarette smoke-induced loss of cilia in the airway epithelium 
                          
MATERIALS AND METHODS
METHODS AND MATERIALS
A total of 80 patients of COPD coming to GGH, MMC were be screened 
for  COPD by  history  clinical  examination  and  PFT.   Patients  with  features 
consistent with copd and FEV1/ FVC ratio less than 0.7 were be chosen for the 
study. The FEV1/FVCratio, reflecting the rate of emptying of the lung, is used to 
define  the  presence  of  an  obstructive  ventilatory  defect.  They  were  be 
categorized according to GOLD criteria using the percentage of predicted FEV1 
for severity of COPD.  Their blood levels of hs-CRP and plasma fibrinogen were 
be measured. The electronic super Spiro machine was used for doing pulmonary 
function tests after giving appropriate instructions and ensuring the patient is not 
having any respiratory infection and repeated twice to measure the best possible 
effort by the patient.  The hs-CRP was measured by nephalometric method using 
the  turbox  analyzer.  Plasma  fibrinogen  was  measured  using  immuno 
turbidimetric method Olympus AU400 analyzer. Other parameters such as BMI, 
ESR,  polymorph  percentage,  pack  years  of  smoking  were  recorded  of 
individuals. A careful history with regard to the patients symptoms of  COPD, 
smoking habits, cardiovascular illness, renal or liver disorders, any connective 
tissue,  autoimmune,  vascullitic  disorders,  diabetes,  hypertension,  peripheral 
vascular disease was obtained.  
A thorough head to  foot  clinical  examination  of  all  the  systems  were 
done.   A  routine  battery  of  investigations  to  test  for  renal,  liver  function, 
diabetes,  presence  of  ischaemic  heart  disease,  or  tuberculosis  was  done  to 
carefully select patients as per exclusion criteria.
Research Design
This is a cross-sectional study assessing the levels of plasma fibrinogen , 
hs-CRP  among other parameters such as ESR, polymorph percent, BMI, pack 
years of smoking,FEV1percent of predicted in patients with COPD involving 80 
participants presenting to MMC, GGH, Chennai.
Study setting
This study was done in the institute of internal medicine in GGH, Madras 
medical  college,  Chennai  with  inputs  and  active  cooperation  from  the 
department of thoracic medicine. GGH, MMC, CHENNAI.
Methodology
This is a cross-sectional study conducted as described above on patients 
in the age group 20-60 years.  Patients, after informed consent were recruited 
into study, if they were eligible as per the criteria below.
Inclusion   criteria
Patients  attending  OPD and  admitted  to  medical  department  in  the 
Government General Hospital with clinical features of COPD, i.e.; cough with 
expectoration, dyspnea, wheeze and FEV1/FVC ratio of less than 0.7 showing 
obstructive features on electronic Spirometry and without any comorbid illness 
are selected for the study.
Exclusion   criteria
          1.  Patients   who are terminally ill, critically or acutely
          2.  Age < 20yrs >60 yrs.
         3.  Diabetics, hypertensive, past history of   M.I, Stroke, TIA
         4.  Any arterial or venous thrombosis, peripheral vascular disease.
         5.  H/o  of  immunological  disorders  like  rheumatoid  arthritis,  SLE, 
ankylosing spondillitis
          6.   H/o cancer, renal disease, liver disorder
          7.   Ongoing infections.
OBSERVATION AND RESULTS
OBSERVATION AND RESULTS
THE study was done on 80 patients presenting to the medical department 
and were selected randomly as per the inclusion criteria and exclusion criteria. 
All  individual  patients  were  informed  of  the  study  and  their  consent  was 
obtained. Pulmonary function tests were done in these patient after excluding the 
conditions listed in the exclusion criteria with careful clinical history and simple 
tests such as RFT, LFT, complete blood counts, ECG,CXR, ECHO, etc. PFT 
was done in the department of thoracic medicine using the electronic super Spiro 
machine and the patients individual FEV1, FVC, FEVI percentage of predicted 
value,  FEV1/FVC was  calculated  and they  were  staged according  to  GOLD 
stage of COPD.  STAGE 4 diseases was excluded.
STASTISTICAL ANALYSIS
Data  analysis  was  done  with  use  of  SPSS,  version  10.  Descriptive 
statistics were used to calculate the frequency, mean, and standard deviation. To 
examine the linear trend of the proportions, trend chi-square was used and to 
find  the  test  of   association  chi-square  was  computed.  The  correlation  of 
variables  i.e.,  age  ,BMI,  ESR,  polymorph  percent  of  total  count,  hs-  CRP, 
plasma fibrinogen with severity of COPD as per GOLD stage was analyzed with 
chi-square test using the Pearson method. The correlation between pack years 
with GOLD stage was analyzed using the anova test followed by the tukey- hsd 
test.  The  correlation  between  the  variables  i.e.,  age  ,BMI,  ESR,  polymorph 
percent of total  count,  hs- CRP, plasma fibrinogen with FEV1 percentage of 
predicted  values  was  analyzed  using  correlation  coefficients.  The  correlation 
between the variables i.e., age ,BMI, ESR, polymorph percent of total count, hs- 
CRP, plasma fibrinogen and FEV1 percentage of  predicted values with pack 
years of smoking was analyzed using correlation coefficients.
BASELINE CHARACTERISTICS
The age composition of the study group was 8.75% in the 20-30 group, 
28.75% in the 30-40 group, 33.75% in the 40-50 group and 28.75 in the 30-40 
group.
TABLE – 2 
BASELINE AGE DISTRIBUTION IN STUDY
Age group frequency percentage
20-30 7 8.75
30-40 23 28.75
40-50 27 33.75
50-60 23 28.75
total 80 100.00
Age Group in years
50-6040-5030-4020-30
N
u
m
b
e
r 
o
f 
P
a
tie
n
ts
30
25
20
15
10
5
0
Among the different age groups there was increasing correlation of age 
with severity as per FEV1  percentage of predicted and GOLD STAGE which 
was found to be statistically significant with a p value of .00071calculated by chi 
square test  indicating the presence of severe disease with increasing age which 
was expected.
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The distribution of the patients recruited to the study in different stages of 
COPD as per GOLD staging is given in the following table.
TABLE – 3 
BASELINE DISTRIBUTION OF GOLD STAGE IN COPD.
GOLD STAGE FREQUENCY PERCENTAGE
STAGE 1 16 20.00
STAGE2 47 58.75
STAGE 3 17 21.25
TOTAL 80 100.00
BODY MASS INDEX(BMI)
The study population BMI was measured and categorized as per standard 
guide lines as given in the following chart.
TABLE – 4 
BASELINE DISTRIBUTION OF BMI IN STUDY POPULATION
Bmi group frequency percentage
Underweight<18.5 1 1.25
Normal 18.6-24.9 30 37.50
Overweight 25-30 29 36.25
Obesity 30-35grade1 16 20.00
Obesity 35-40 grade2 3 3.75
Morbid obesity >40 1 1.25
total 80 100.00
BMI Group
Morbid Obesity
Obesity Grade II
Obesity Grade I
Over w
eight
Normal
Under w
eight
N
u
m
b
e
r 
o
f 
P
a
tie
n
ts
20
15
10
5
0
Gold Stage
Stage I
Stage II
Stage III
Among the different BMI groups the occurrence of COPD and the range 
of its study was analyzed. It was found that there was no statistically significant 
correlation of either increasing or decreasing BMI with increasing severity of 
COPD. The p value was .82441. This might due to the fact that our study group 
comprised of relatively well compensated patients without any active illness and 
other  comorbities  and  the  fact  that  stage  4  copd  patients  were  not  included 
because  of  the  exclusion  criteria.   Although  other  studies  have  shown  a 
decreasing trend of BMI with increasing severity, i.e. Di Francia et al, our study 
did not show such a correlation .we suggest more studies with a higher number 
of patients to be done in this regard.
TABLE – 5 
CORRELATION OF BMI WITH GOLD STAGE
BMI
STAGE 1 STAGE 2 STAGE 3
Percentage Distribution
UNDERWEIGHT 
1no
- 1% -
NORMAL
30no
23.3% 56.7% 20%
OVERWEIGHT 17.2% 62.1% 20.7%
29no
GRADE 1 OBESITY 
16 no
25% 56.3% 18.8%
GRADE 2 OBESITY  
3 no
- 33.3% 66.7%
MORBIDLY OBESE
 1 no
- 100% -
TOTAL 20% 58.8% 21.2%
PVALUE .82441
PACKYEARS
The mean pack years of smoking among the patients was calculated. The 
distribution is given in the table below.
TABLE – 6 
DISTRIBUTION OF PACK YEARS WITH AGE
Age groups Pack years mean Standard deviation
20-30 26.43 15.20
30-40 28.91 14.06
40-50 31.85 9.52
50-60 32.39 12.42
The distribution of the pack years of smoking with the severity of COPD 
was  assessed  anova  test  followed  by  tukey-  hsd  test.  It  was  found  that  a 
statistically significant difference was found between stages 1 and 3.
 The following table shows the details
TABLE – 7  
GOLD STAGE AND PACKYEARS
Gold stage Pack years mean Standard deviation
Stage 1 23.44 14.80
Stage 2 31.49 11.42
Stage 3 35.29 8.92
GOLD Stage
Stage IIIStage IIStage I
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It is seen that with increasing pack years of smoking the severity of the 
disease as per GOLD stage is also increasing. The statistical significance was 
calculated using multiple range tukey- hsd test and was found to be statically 
significant at a p value of .040.
The  correlation  of  other  variables  like  FEV1  percentage  of  predicted, 
ESR,  polymorphs  percentage,  hs-CRP,  plasma fibrinogen  with  pack  years  is 
given in the following table.
TABLE – 8  
CORRELATION OF  INFLAMMATORY MARKERS   
WITH PACKYEARS
Pack years Correlation coef P value
Age .155 .168
Esr .4327 .006
Polymophs% .2269 .043
Hs - crp .4404 .006
Plasma fibrinogen .2872 .010
FEV1 percentage pred -.3306 .003
As we can see from the data above it is seen in our study that the numbers 
of pack years of smoking is significantly correlated with the levels of systemic 
inflammatory markers and decreasing lung function in the form of decreasing 
FEV1 percentage of the predicted value. The correlation was studied using spss 
software analysis.
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The polymorph percentage in the study group of patients was estimated 
by  auto  analyzer.  The  group  was  divided  into  normal  (40-60%)  and 
abnormal(>61%). The distribution in the study group is given in the following 
diagram and chart.
TABLE – 9 
POLYMORPH PERCENTAGE DISTRIBUTION
Polymorph percent frequency percentage
Normal (40-60%) 59 73.75%
Abnormal (>61%) 21 26.25%
total 80 100%
The data collected in the study showed that most individuals were with 
normal  polymorph percent  group.  The  correlation  assessed  between the  poly 
morph and the severity of COPD as per GOLD staging and FEVI percentage of 
predicted value did not show any correlation when tested with chi-square test 
and  Pearson method.  The  p  values  >.05  and the  correlation  coefficient  with 
FEV1 predicted percentage was .349 with a p value >.05. But the polymorph 
percentage  shows  a  positive  correlation  with  pack  years  of  smoking  with  a 
correlation coefficient of .2269 with a statistically significant p value of .043.
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ESR
The ESR of the individual patients  was measured using the wintrobes 
method. The distribution as normal range of <15mm and abnormal of >16 was 
seen and is shown in the following table and diagram.
TABLE - 10  
ESR DISTRIBUTION IN STUDY POPULATION
Esr group Frequency percentage
Normal<15mm 20 25%
Abnormal>16 60 75%
Total 80 100%
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It was observed that 75% of the participants had baseline levels of ESR 
above  normal  in  the  absence  of  causes  of  inflammation  other  than  COPD. 
Among the ESR abnormal group most no of patients with abnormal ESR were 
found in stages 2 and 3. The correlation between abnormal increased levels of 
ESR and increasing severity of COPD was assessed using chi-square test and 
Pearson method and the p value was not significant ie,.34091.  This could be 
because of the n value of the study. But it was found that  ESR had a strong 
negative  correlation  with  the  percentage  of  predicted  FEV1.  The  correlation 
coefficient was -.4327 with a p value of .101. This could be because percentage 
of predicted FEV1 which is a continuous variable shows a better staging of the 
copd disease than the GOLD stage. The following table gives the assessment of 
correlation between abnormal increased levels of ESR and increasing severity of 
COPD as per gold stage.
TABLE – 11 
CORRELATION OF ESR WITH GOLD STAGE
ESR
Stage 1 Stage 2 Stage 3 Total %
Percentage Distribution
Normal (20 Nos) 25% 45% 30% 25%
Abnormal (60 Nos) 18.3% 60.3% 18.3% 75%
Total (80 Nos) 20% 58.8% 21.3% 100%
hs- CRP
The main parameters  i.e.,  the systemic markers of inflammation being 
assessed in this study i.e., hs- CRP and plasma fibrinogen were calculated. Their 
distribution in the study population is given in the following table and diagram.
TABLE – 12
DISTRIBUTION OF hs-CRP AND PLASMA FIBRINOGEN VALUES
hs- CRP Frequency Percentage
Normal <0.3mg/dl 6 7.50%
Abnormal >0.3mg/dl 74 92.50%
Plasma fibrinogen
Normal <400mg/dl 48 60%
Abnormal >401mg/dl 32 40%
Total 80 100%
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TABLE – 13 
CORRELATION OF hs-CRP WITH GOLD STAGE
Hs-CRP STAGE1 STAGE2 STAGE3 TOTAL
NORMAL<0.3 33.3 50 16.7 6
ABNORMAL>0.3 18.9 59.5 21.6 74
TOTAL 20 58.8 21.3 80
P value .69585
The majority of the study populace had elevated levels of hs-CRP i.e., 
92.50%. Among the patients with elevated hs- CRP it was higher in patients with 
increasing  severity.  The  correlation  assessed  by  chi-square  test  and  Pearson 
method was not found to be statistically significant with a p value >.05.  But 
even in  that  data  it  was  found  that  increasing  severity  of  copd had  a  linear 
relation with increasing levels of hs-CRP and it had a strong negative correlation 
with percentage of predicted FEV1 the correlation coefficient calculated being 
-2.784 with a p value of.012. This discrepancy can be explained by the smaller n 
value in our study and the percentage of predicted FEV1 being a continuous 
variable and a better predictor of severity in a small group than GOLD stage.
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PLASMA FIBRINOGEN
The distribution of the levels of plasma fibrinogen is the study populace 
(table above) and the bar diagram to show the distribution among the different 
stages of COPD as per  GOLD CRITERIA  is given below.
                                                                                  
The data shows that majority of the study group patients  have normal 
levels  of  plasma  fibrinogen.ie,60%.the  correlation  with  increasing  levels  of 
COPD  a per  GOLD  stage was measured using chi-square test and Pearson 
method. The correlation was not statistically significant with a p value of>.05. 
The table is given below.
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TABLE – 14 
CORRELATION OF PLASMA FIBRINOGEN WITH GOLD STAGE
Plasma fibrinogen
Stage 1 Stage 2 Stage 3 Total
Percentage Distribution
Normal<400mg/dl 20.8 60.4 18.8 48
Abnormal>401mg/dl 18.8 56.3 25.0 32
total 20 58.8 21.3 80
P value  .797
The scatter diagram showing the correlation of plasma fibrinogen with 
FEV1 percentage of  predicted  is  given below.  But  the  data  seen shows that 
among patients with normal and abnormal levels of plasma fibrinogen the levels 
were  higher  with  increasing  stage  of  the  disease  and  the  scatter  diagram 
correlating plasma fibrinogen with percentage of predicted FEV1 shows a linear 
negative relation even though the finding is not statistically significant, p>.05.
TABLE – 15 
CORRELATION OF INFLAMMATORY MARKERS WITH FEV1 
PERCENTAGE OF PREDICTED VALUE
FEV1 ESR hs-CRP Plasma 
fibrinogen
Correlation coef -.1846 -.2784 -.1022
P value
<.05- significant
.101 .012 .367
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DISCUSSION
DISCUSSION
In  most  patients  with  COPD,  the  disease  process  affects  the  airways 
(leading  to  airway  remodeling)  and parenchyma (leading  to  emphysema and 
poor  gas  exchange).  The  predominant  symptoms  of  COPD  are  chronic 
(productive) cough and exertional dyspnea. However, a substantial proportion of 
COPD  patients  have  extra-pulmonary  symptoms  and  signs.  For  instance,  in 
advanced  COPD,  weight  loss  and  cachexia  are  common.  Other  common 
manifestations  include  skeletal  muscle  weakness,  osteoporosis,  heart  failure, 
cardiac  arrhythmias,  ischemic  heart  disease,  stroke,  depression,  and  cancer. 
Interestingly, the severity of the underlying COPD modifies the risks of these 
extra-pulmonary manifestations. 
Despite the awareness about smoking and its well known side effects, the 
problem of  COPD continues  to grow.  The ever  changing concepts  about  the 
pathogenesis of COPD and its effects we need to keep abreast with newer facets 
of  COPD from the  knowledge  of  which  newer  modalities  of  treatment  both 
implicit  as  well  as  in  protocol  form  for  prophylaxis  as  well  as  secondary 
prevention  can  elucidated  with  further  knowledge  of  the  risk  factors  for  the 
systemic effects and other important organ damage due to inflammation. The 
study  of  the  distribution  of  these  markers  of  inflammation  among  Indian 
population was important for forming any guidelines on treatment.  There is a 
paucity of such studies in the Indian population. There fore this cross-sectional 
study was done with a aim to observe for any consistent correlation with severity 
of COPD and the markers of inflammation.
Previous  studies  (LINDA et  al)  have  shown an  increasing  severity  of 
COPD with increasing age which our study also showed a similar trend possibly 
related  to  the  increase  in  the  duration  of  smoking  as  shown by  pack  years. 
Among the different age groups there was increasing correlation of age with 
severity as per FEV1 percentage of predicted as well as GOLD STAGE which 
was found to be statistically significant with a p value of .00071calculated by chi 
square test indicating the presence of severe disease with increasing age.
The  correlation  between  increasing  severity  of  COPD and  decreasing 
BMI  has  been  observed  in  some  studies48 [Creutzberg  et  al.  1998].  This 
observation  of  correlation  was  not  seen  in  our  study;  possibly  because  of 
rigorous  selection  of  patients  as  per  the  exclusion  criteria  (ill  patients  were 
excluded).  Also  the  proposed  mechanism  behind  the  decrease  in  BMI  was 
alteration in the level of leptin, which is dependant on other regulators such as 
those with predisposition to obesity. Other measures of cachexia and skeletal 
muscle  wasting  i.e.,  mid  thigh  circumference  body  impedance  measurement 
technique and DEXA can be better markers of severity of early cachexia and 
wasting51.
ESR and polymorph percent of total WBC count are nonspecific markers 
of inflammation which are found to vary highly among individuals. There have 
been studies which have used these markers for assessing severity of copd. But 
the inflammation in COPD is at a low level and is chronic. We wanted to see if 
there were minor variations in these markers, if present could be used as low 
cost markers of inflammation in COPD or to possibly sub stratify patients with 
COPD49.  The data collected in the study showed that most individuals were with 
normal  polymorph percent  group.  The  correlation  assessed  between the  poly 
morph and the severity of COPD as per GOLD staging and FEVI percentage of 
predicted value did not show any correlation when tested with chi-square test 
and  Pearson method.  The  p  values  >.05  and the  correlation  coefficient  with 
FEV1 predicted percentage was .349 with a p value >.05.  But the polymorph 
percentage  shows  a  positive  correlation  with  pack  years  of  smoking  with  a 
correlation coefficient of .2269 with a statistically significant p value of .043.  It 
was observed that  75% of the participants  had baseline levels of ESR above 
normal in the absence of causes of inflammation other than copd. Among the 
ESR abnormal group most no of patients  with abnormal ESR were found in 
stages 2 and 3. The correlation between abnormal increased levels of ESR and 
increasing severity  of  COPD was assessed using chi-square test  and Pearson 
method and the p value was not significant ie,.34091. This could be because of 
the  n  value  of  the  study.  But  it  was  found  that  ESR had  a  strong  negative 
correlation with the percentage of predicted FEV1. The correlation coefficient 
was -.4327 with a p value of .101. This could be because percentage of predicted 
FEV1 which is a continuous variable shows a better staging of the copd disease 
than the GOLD stage. Therefore it is possible that ESR can be used as a marker 
to corroborate the patients’ history of smoking in a particular patient.
C-reactive protein (CRP) is an acute phase reactant protein measured in 
plasma, synthesized by the liver in response to inflammation. CRP is elevated in 
patients with stable COPD, regardless of stage50, and in patients the treatment of 
exacerbations is associated with a decline in CRP. In our study majority of the 
populace had elevated levels of hs-CRP i.e., 92.50%. Among the patients with 
elevated  hs-  CRP  it  was  higher  in  patients  with  increasing  severity.  The 
correlation assessed by chi-square test and Pearson method was not found to be 
statistically significant with a p value >.05.  But even in that data it was found 
that increasing severity of copd had a linear relation with increasing levels of hs-
CRP and it had a strong negative correlation with percentage of predicted FEV1 
the correlation coefficient  calculated being -2.784 with a p value of.012.This 
discrepancy  can  be  explained  by  the  smaller  n  value  in  our  study  and  the 
percentage of predicted FEV1 being a continuous variable and a better predictor 
of  severity  in  a  small  group  than  GOLD  stage.  Therefore  it  is  prudent  to 
conclude that the levels of hs-CRP increases with severity of COPD suggesting 
the increasing grade of micro inflammatory process in COPD, possibly causing 
increasing pre disposition to cardiovascular manifestations of COPD. It is also 
possible  that  hs-CRP  can  be  used  as  an  early  marker  of  impending 
exacerrebration  since  in  other  studies  it  has  been  found  to  decrease  with 
treatment.  It  can also be used to  sub classify  patients  with COPD. It  is  also 
probable to conclude that the percentage of predicted FEV1 is a better variable 
to stratify patients according to severity when dealing with smaller groups or 
individuals  as  it  a  continuous variable giving more concrete  measurement  of 
individual pulmonary dysfunction.
It  was  reported  that  COPD patients  had  significantly  higher  levels  of 
fibrinogen  than  healthy  subjects.   Wedzicha  et  al    reported  that  plasma 
fibrinogen levels were elevated in stable COPD patients and further increased 
during  exacerbations,  which  was  associated  with  increased  serum interleukin 
(IL)-6. IL-6 is capable of modulating the number and/or activity of important 
inflammatory cells. IL-6 is synthesized by airway epithelium, macrophages and 
several  other  cells  at  sites  of  inflammation17,18.  Fibrinogen,  an  acute-phase 
reactant and a blood-clotting factor, is synthesized by hepatocytes and released 
in large amounts into the circulation, primarily in response to IL-6 stimulation52. 
Therefore, it is possible that fibrinogen could be used as a marker of ongoing 
airway inflammation and lung tissue injury in the absence of other possibilities. 
We did not look for levels of IL-6, but it can be speculated  that this cytokine 
plays  a  role  in  the  rise  of  fibrinogen  in  our  cases  due  to  the  ongoing 
inflammatory  processes.  Our  data  shows  that  majority  of  the  study  group 
patients have normal levels of plasma fibrinogen.ie,60%. The correlation with 
increasing levels of COPD as per GOLD stage was measured using chi-square 
test and Pearson method. The correlation was not statistically significant with a p 
value  of>.05.  But  the  data  seen shows that  among patients  with normal  and 
abnormal  levels  of  plasma fibrinogen the  levels  were  higher  with  increasing 
stage  of  the  disease  even  though  the  finding  is  not  statistically  significant 
p>.05.this again we feel can be due to the limitation of the smaller sample size. 
Moreover the study patients were in stable condition without any exacerbation in 
which plasma fibrinogen has been found to be elevated more. Still even with our 
data we see that plasma fibrinogen base line levels are increased with higher 
severity of COPD as per the FEV1 percentage of predicted value. This finding 
has implications for people with COPD who are at higher risk for peripheral and 
central,  systemic and pulmonary vascular thrombosis in whom prophylaxis to 
prevent such a catastrophe from happening.
Therefore we conclude that copd is a multisystem disease, with chronic 
micro level inflammation that has several systemic manifestations. The markers 
of this inflammation can have a vital role in pathogenesis of these comorbid 
illnesses  such  as  cachexia,  osteoporosis,  cardiovascular  morbidity,  cancer, 
depression  and  anxiety.  Also  these  markers  such  as  hs-  CRP  and  plasma 
fibrinogen can be used to predict outcomes in patients with COPD. These along 
with other markers could be used to sub classify patients with COPD into several 
groups and approach them individuals accordingly.
LIMITATIONS OF STUDY
LIMITATIONS OF STUDY
1) We found that in our study there was some limitations with the sample 
size which precluded us from getting statistical significance with regard 
to certain variables with the severity of COPD.
2) The exclusion criteria that we put forward were limiting our ability to 
correlate the variables that we had chosen with severity as assessed by 
GOLD staging of COPD.
3) The study has only male patients which precluded us from studying these 
variables distribution in the female population.
4) Our study comprised of patients with COPD who were not functionally 
incapacitated  to  limit  everyday  activities  though  the  symptoms  had 
prompted them to access health care which could probably be associated 
with the lack of correlation between certain variables and the severity as 
measured by GOLD stage.
We suggest that more studies are needed in Indian population regarding 
these  markers  of  inflammation  occurring  in  COPD,  with  more  number  of 
patients  with  better  markers  of  disease  and  systemic  markers  to  come  to  a 
conclusion on the various use of these markers in making therapeutic guidelines 
and use in prognostification.
CONCLUSIONS
CONCLUSIONS
1. hs-CRP  has  been  found  to  be  significantly  elevated  with  increasing 
severity of COPD which could lead to increased predisposition to cardio 
vascular morbidity and mortality.
2. Plasma  Fibrinogen  levels  were  not  found  to  be  significant  marker  of 
COPD coagulopathy  in  our  study or  stable  COPD.   More  studies  are 
needed.
3. Polymorph percentages, ESR are not significant markers of inflammation 
in COPD.
4. ESR, hs-CRP, Plasma Fibrinogen are markers of increasing exposure to 
smoking.
5. Physicians need to approach COPD as a multi system disease and identify 
patients with the associated co-morbidities of COPD vis-à-vis the extra 
pulmonary manifestations of COPD.
ANNEXURE
 PROFORMA
 MASTER CHART
 ETHICAL COMMITTEE CERTIFICATE
 ABBREVIATIONS
PROFORMA
NAME: AGE: SEX:
ADDRESS:
OCCUPATION:
SYMPTOMS:   COUGH/EXPECTORATION/DYSPNOEA/WHEEZING/ 
FEVER. etc..
SMOKER:    PRESENT/PAST/NEVER          
IF PRESENT, HOW MANY PACK YEARS
IF PAST, HOW MANY YEARS OF ABSTAINANCE
DIABETES:        YES/NO                                            IF YES,  NO. OF 
YEARS
HYPERTENSION:  YES/NO                                       IF YES, NO. OF 
YEARS
IHD:
CVA:
PERIPHERAL VASCULAR DISEASE:
IMMUNOLOGICAL/INFLAMMATORY DISORDERS:
FEVER/ARTHRALGIA/ARTHRITIS/RASH/ANEMIA/VASCULITIS/HEMATU
RIA/SCLERITIS/OTHER
RENAL DISORDERS:
LIVER DISORDERS:
CANCER:
CLINICAL FINDINGS: 
 
PR:                    PERIPHERAL PULSES:                   RR: 
BP:
CVS:                                                                             RS:
CNS:           P/A
LAB INVESTIGATIONS:
HB:                PCV:                     TC:                  DC:                            ESR: 
PLATELETS:
BLOOD SUGAR:                   FBS:                  PPBS:
BLOOD UREA:                      S. CREATININE:                   TOTAL PROTEIN: 
ALBUMIN:
TOTAL BILIRUBIN:              DIRECT BILIRUBIN:  SGOT:
SGPT:  SAP:
HSCRP: 
               
PLASMA FIBRINOGEN:    
           
CHEST XRAY:
ECG:
ECHO:
PULMONARY FUNCTION TESTS:
FEV1:                          FVC:                               FEV1/FVC:                GOLD 
STAGE:
FEV1 percentage of predicted:
IMPRESSION:
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1 abbas.m 50 M 30.86 2.1 4.7 0.44 51% stage3 23 66 1.94 404 50
2 abdul 39 M 27.77 3.4 5.3 0.64 70% stage2 26 48 0.94 367 25
3 ajaxkumar          29 M 23.02 3.4 4.5 0.63 87% stage1 18 50 0.73 450 15
4 anandaraj 42 M 27.50 1.7 3.7 0.60 71% stage2 29 60 2.3 432 35
5 anbu 28 M 24.91 3.3 4.8 0.68 80% stage1 32 55 2.1 557 5
6 andrew 57 M 21.60 2.8 4.1 0.68 70% stage2 12 40% 0.74 389 10
7 arokiyadoss          47 M 19.14 1.5 3 0.50 48% stage3 56 66 0.8 560 40
8 arokiyaswamy      57 M 21.60 2.8 4.1 0.68 70% stage2 11 48 0.54 370 20
9 babu 31 M 25.68 4 5.8 0.68 85% stage1 9 52 0.3 257 10
10 bakyaraj 46 M 24.72 1.6 3 0.53 47% stage3 30 50 0.9 393 40
11 baskar 32 M 20.76 3.4 4.9 0.69 85% stage1 32 70 0.83 481 10
12 chandra 46 M 29.41 2.3 3.8 0.60 67% stage2 10 54 0.92 560 15
13 chockalingam       35 M 27.25 2.5 3.9 0.64 69% stage2 8 45 0.4 234 20
14 christo 39 M 24.76 1.6 2.4 0.64 66% stage2 33 49 1 520 20
15 daniel 56 M 30.43 1.6 2.6 0.61 66% stage2 31 49 0.73 249 25
16 dharma.p 40 M 27.98 1.7 3.5 0.48 56% stage2 22 56 0.8 470 20
17 harish 23 M 18.51 3 5.5 0.54 63% stage2 44 54 1.9 580 45
18 james 59 M 23.82 2 5 0.40 44% stage3 12 56 1.7 455 40
19 johnson 33 M 23.87 3.3 4.8 0.68 84% stage1 6 43 0.5 341 25
20 k.moorthy 55 M 31.56 2.5 4 0.60 75% stage2 8 42 0.3 300 20
21 kamath 44 M 27.33 2.2 4.3 0.60 62% stage2 40 65 1.2 474 25
22 karthick 27 M 23.70 2.7 4 0.67 65% stage2 22 50 0.94 540 40
23 karupaiah 39 M 27.70 3.4 5.4 0.63 77% stage2 21 43 0.5 380 20
24 kathaan 39 M 34.22 2 2.9 0.68 74% stage2 38 79 2 552 40
25 kathyaya 55 M 34.37 2 3 0.66 68% stage2 22 56 1.9 487 40
26 krippa 58 M 20.37 1.6 4.4 0.36 41% stage3 33 49 2.3 600 50
27 krishnan 53 M 27.33 2.2 4.3 0.60 62% stage2 56 77 2 576 50
28 kulanchi 36 M 31.25 3.6 5.5 0.65 80% stage1 39 48 1.4 400 20
29 mani 46 M 21.60 2.1 4.6 0.45 55% stage2 22 47 1.3 465 25
30 mani.p 55 M 35.46 1.6 3.2 0.50 48% stage3 12 45 0.7 333 20
31 manickam 47 M 23.74 3 4.3 0.60 85% stage1 28 55 1.2 463 25
32 mariapan 44 M 28.80 2 4 0.50 50% stage3 9 48 0.5 290 20
33 munivel 48 M 25.61 3 5.2 0.60 71% stage2 29 60 2.3 482 35
34 murugan 43 M 27.50 1.7 3.7 0.45 41% stage3 34 66 2.2 456 30
35 muthu 57 M 21.60 2.8 4.1 0.68 70% stage2 32 64 1.2 404 30
36 narasiman 37 M 16.04 2.6 5.4 0.48 59% stage2 36 55 2 560 45
37 narayanan 44 M 34.37 2 3.5 0.57 64% stage2 44 67 1.6 444 40
38 padavattan 56 M 29.47 2.2 3.7 0.59 70% stage2 12 56 0.3 300 30
39 padurangan          41 M 31.07 2 4 0.50 52% stage3 44 68 1.2 450 35
40 palanivel 41 M 26.86 3 4.5 0.66 73% stage2 36 62 0.46 480 35
41 pappan 58 M 41.40 2 3.4 0.58 71% stage2 12 55 0.33 313 30
42 Partha 40 M 26.50 2 4 0.50 76% stage2 45 40 1.3 480 40
43 parthiban 52 M 29.75 2.9 4.3 0.67 82% stage1 20 45 0.4 381 30
44 pitchandi 57 M 25.94 3.1 4.8 0.64 81% stage1 18 80 1.3 300 35
45 r.ahmed 42 M 19.40 2.2 4 0.55 64% stage2 32 67 1.6 256 30
46 raghu 37 M 22.22 2 5 0.40 45% stage3 22 45 0.8 307 35
47 raja 37 M 22.74 2 4.5 0.44 50% stage3 12 48 0.3 276 35
48 rajan 44 M 28.80 2 4.9 0.43 50% stage3 32 56 0.99 345 35
49 rajiv 33 M 24.46 3.1 4.5 0.68 82% stage1 46 68 1.6 360 40
50 ramu 59 M 23.80 2.5 5 0.50 62.50% stage2 21 48 0.8 250 10
51 ravi 32 M 20.76 3.4 4.7 0.70 85% stage1 10 64 0.8 263 10
52 riaz 38 M 26.64 3.2 4.8 0.68 84% stage1 8 48 0.4 445 40
53 s.prakash 42 M 19.40 2.2 4 0.55 64% stage2 18 66 0.9 296 10
54 sakarai 59 M 19.40 2.2 4 0.55 64% stage2 22 55 0.84 290 40
55 sakthi 27 M 23.87 2.7 4 0.67 65% stage2 22 50 1.2 337 40
56 salman 39 M 27.77 3.4 5.4 0.63 77% stage2 20 56 1.4 391 40
57 santham 47 M 26.77 2.5 4.6 0.54 67% stage2 32 54 1.2 278 40
58 sathyam 56 M 30.61 2.4 4 0.60 68% stage2 44 60 2 560 40
59 sebastian 59 M 21.48 1.6 3 0.53 57% stage2 21 48 1 300 40
60 shankar 41 M 26.86 3 4.5 0.66 73% stage2 18 60 1.2 317 45
61 shatru 48 M 39.50 1.6 3.3 0.48 50% stage3 12 42 0.4 243 25
62 sk. Senthil           38 M 34.28 2.4 4 0.60 65% stage2 30 50 1 352 45
63 somu 55 M 19.53 1.6 3 0.53 52% stage2 34 56 0.81 300 60
64 soori 54 M 20.70 2.2 4.2 0.52 61% stage2 16 55 1.2 316 40
65 sourimuthu           50 M 25.83 2.6 4 0.65 70% stage2 34 66 1.7 321 35
66 sukumar 55 M 31.64 3 4.4 0.68 76% stage2 18 60 1.3 400 35
67 suresh 59 M 29.06 2.7 4.2 0.64 81% stage1 23 56 0.94 278 25
68 swaminathan        29 M 23.87 2.2 4.7 0.46 55% stage2 16 66 1.2 284 20
69 thiru 30 M 39.50 1.8 3.6 0.50 56% stage2 34 57 1.34 300 20
70 varadan 48 M 27.77 1.7 4.8 0.35 40% stage3 36 60 2.5 458 40
71 velan 49 M 29.41 1.6 3.3 0.48 48% stge3 12 45 0.7 297 25
72 velu 33 M 26.80 3 4.5 0.66 73% stage2 10 44 0.3 233 40
73 vimalraj 38 M 31.25 2.6 3.7 0.70 81% stage1 34 66 2.1 442 60
74 williams 59 M 23.84 2.5 4.3 0.58 69% stage2 14 50 1.3 290 25
75 zakeer 43 M 31.37 1.7 3.7 0.43 43% stage3 33 60 2.7 363 40
76 paneer 36 M 30.93 3 4.3 0.69 81% stage1 23 67 1 245 15
77 zafarullah 48 M 29.73 3.1 4.6 0.67 79% stage2 22 62 1.5 356 25
78 manish 39 M 32.28 3.3 4.8 0.68 86% stage1 11 50 0.2 234 10
79 shankar 44 M 31.66 2.2 3.3 0.66 75% stage2 24 56 1.2 344 20
80 vellayan 33 M 26.80 3 4.5 0.66 73% stage2 10 44 0.3 233 40

ABBREVIATIONS
COPD : CHRONIC OBTRUCTIVE PULMONARY DISEASE
FEVI :  FORCED EXPIRATORY VOLUME IN 1 SEC
FVC  : FORCED VITAL CAPACITY 
GOLD : GLOBAL INITIATIVE ON OBSTRUCTIVE LUNG 
DISEASES
IL-6 : INTERLEUKIN-6
hs-CRP : HIGHLY SENSITIVE C-REACTIVE PROTEIN.
IHD : ISCHAEMIC HEART DISESE
RFT : RENAL FUNCTION TEST
LFT : LIVER FUNCTION TEST
CBC : COMPLETE BLOOD COUNT
PFT : PULMONARY FUNCTION TEST
ESR : ERYTHROCYTE SEDIMENTATION RATE
TC : TOTAL WBC COUNT
DC : DIFFERENTIAL COUNT
TGF : TISSUE GROWTH FACTOR
IGF : INSULIN LIKE GROWTH FACTOR
TNF : TUMOUR NECROSIS FACTOR
IP-10 : INDUCIBLE PROTEIN 10
MMP : MATRIX METALLOPROTEIN
IL-1R : ITERLEUKIN RECEPTOR TYPE 1
Kda : KILODALTON
DEXA : DUAL ENERGY X-RAY ABSORPIMETRY
MI : MYACARDIAL INFARCTION
TIA : TRANSIENT ISCHAEMIC ATTACK
Vwf : VON WILLIEBRAND FACTOR
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